Actinium Pharmaceuticals ATNM Stock
Actinium Pharmaceuticals Price Chart
Actinium Pharmaceuticals ATNM Financial and Trading Overview
| Actinium Pharmaceuticals stock price | 1.02 USD |
| Previous Close | 1.03 USD |
| Open | 1.02 USD |
| Bid | 0 USD x 20000 |
| Ask | 0 USD x 30000 |
| Day's Range | 1.02 - 1.05 USD |
| 52 Week Range | 0.95 - 1.89 USD |
| Volume | 70.96K USD |
| Avg. Volume | 182.05K USD |
| Market Cap | 32.32M USD |
| Beta (5Y Monthly) | -0.052 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5 USD |
ATNM Valuation Measures
| Enterprise Value | -8296759 USD |
| Trailing P/E | N/A |
| Forward P/E | -2.942857 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 359.06937 |
| Price/Book (mrq) | 14.109589 |
| Enterprise Value/Revenue | -92.186 |
| Enterprise Value/EBITDA | 0.327 |
Trading Information
Actinium Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.052 |
| 52-Week Change | -39.41% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 1.89 USD |
| 52 Week Low | 0.95 USD |
| 50-Day Moving Average | 1.18 USD |
| 200-Day Moving Average | 1.31 USD |
ATNM Share Statistics
| Avg. Volume (3 month) | 182.05K USD |
| Avg. Daily Volume (10-Days) | 145.37K USD |
| Shares Outstanding | 31.37M |
| Float | 31.04M |
| Short Ratio | 9.99 |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 20.60% |
| Shares Short | 1.08M |
| Short % of Float | 3.47% |
| Short % of Shares Outstanding | 3.45% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -28346.66% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.95% |
| Return on Equity (ttm) | -167.66% |
Income Statement
| Revenue (ttm) | 90K USD |
| Revenue Per Share (ttm) | 0.003 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 90K USD |
| EBITDA | -25347000 USD |
| Net Income Avi to Common (ttm) | -23471000 USD |
| Diluted EPS (ttm) | -0.76 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 42.13M USD |
| Total Cash Per Share (mrq) | 1.34 USD |
| Total Debt (mrq) | 1.52M USD |
| Total Debt/Equity (mrq) | 65.93 USD |
| Current Ratio (mrq) | 5.887 |
| Book Value Per Share (mrq) | 0.073 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -22876000 USD |
| Levered Free Cash Flow (ttm) | -14791000 USD |
Profile of Actinium Pharmaceuticals
| Country | United States |
| State | NY |
| City | New York |
| Address | 100 Park Avenue |
| ZIP | 10017 |
| Phone | 646 677 3870 |
| Website | https://www.actiniumpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 25 |
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Q&A For Actinium Pharmaceuticals Stock
What is a current ATNM stock price?
Actinium Pharmaceuticals ATNM stock price today per share is 1.02 USD.
How to purchase Actinium Pharmaceuticals stock?
You can buy ATNM shares on the NYSE American exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Actinium Pharmaceuticals?
The stock symbol or ticker of Actinium Pharmaceuticals is ATNM.
Which industry does the Actinium Pharmaceuticals company belong to?
The Actinium Pharmaceuticals industry is Biotechnology.
How many shares does Actinium Pharmaceuticals have in circulation?
The max supply of Actinium Pharmaceuticals shares is 31.37M.
What is Actinium Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Actinium Pharmaceuticals PE Ratio is now.
What was Actinium Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Actinium Pharmaceuticals EPS is -0.76 USD over the trailing 12 months.
Which sector does the Actinium Pharmaceuticals company belong to?
The Actinium Pharmaceuticals sector is Healthcare.
Actinium Pharmaceuticals ATNM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NYSE American Composite Index
XAX
US
|
7941.57 USD — |
-0.43
|
— — | 7866.9 USD — | 8009.21 USD — | — - | — — |
- {{ link.label }} {{link}}